Tandem Diabetes Care (NSDQ:TNDM) has closed its previously-announced underwritten public offering of 30 million shares of common stock at $2.00 apiece.
The San Diego, Calif.-based company reeled in $69 million from the offering, after underwriters exercised an option to buy 4.5 million additional shares of Tandem’s common stock.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem closes $69m underwritten public offering appeared first on MassDevice.